ARS Pharmaceuticals Inc. (NASDAQ: SPRY) has experienced a decline in its stock price by -10.34 compared to its previous closing price of 8.51. However, the company has seen a fall of -1.55% in its stock price over the last five trading days.
Is It Worth Investing in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Right Now?
Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
The average price suggested by analysts for SPRY is $16.67, which is $7.87 above the current market price. The public float for SPRY is 61.88M, and currently, shorts hold a 5.86% of that float. The average trading volume for SPRY on May 26, 2023 was 1.43M shares.
SPRY’s Market Performance
SPRY’s stock has seen a -1.55% decrease for the week, with a 17.38% rise in the past month and a -7.96% fall in the past quarter. The volatility ratio for the week is 11.89%, and the volatility levels for the past 30 days are at 12.08% for ARS Pharmaceuticals Inc. The simple moving average for the past 20 days is 7.73% for SPRY’s stock, with a 14.93% simple moving average for the past 200 days.
SPRY Trading at 9.56% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.93% of loss for the given period.
Volatility was left at 12.08%, however, over the last 30 days, the volatility rate increased by 11.89%, as shares surge +18.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.07% lower at present.
During the last 5 trading sessions, SPRY fell by -1.55%, which changed the moving average for the period of 200-days by +53.21% in comparison to the 20-day moving average, which settled at $7.14. In addition, ARS Pharmaceuticals Inc. saw -10.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Shawver Laura, who sale 42,900 shares at the price of $5.31 back on May 09. After this action, Shawver Laura now owns 210,346 shares of ARS Pharmaceuticals Inc., valued at $227,799 using the latest closing price.
Shawver Laura, the Director of ARS Pharmaceuticals Inc., sale 57,100 shares at $6.16 during a trade that took place back on May 08, which means that Shawver Laura is holding 210,346 shares at $351,736 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -2698.78 for the present operating margin
- +75.76 for the gross margin
The net margin for ARS Pharmaceuticals Inc. stands at -2635.41. Equity return is now at value -30.70, with -29.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 51.01.
Conclusion
In conclusion, ARS Pharmaceuticals Inc. (SPRY) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
